Reliability and convergent validity of two outcome instruments for pemphigus M Rosenbach, DF Murrell, JC Bystryn, S Dulay, S Dick, S Fakharzadeh, ... Journal of investigative dermatology 129 (10), 2404-2410, 2009 | 242 | 2009 |
The diagnostic use of immunohistochemical surrogates for signature molecular genetic alterations in gliomas J Tanboon, EA Williams, DN Louis Journal of Neuropathology & Experimental Neurology 75 (1), 4-18, 2016 | 114 | 2016 |
Intratumoral heterogeneity and TERT promoter mutations in progressive/higher-grade meningiomas TA Juratli, C Thiede, MVA Koerner, SS Tummala, D Daubner, ... Oncotarget 8 (65), 109228, 2017 | 110 | 2017 |
A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases RSP Huang, J Haberberger, E Severson, DL Duncan, A Hemmerich, ... Modern Pathology 34 (2), 252-263, 2021 | 99 | 2021 |
DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome TA Juratli, D McCabe, N Nayyar, EA Williams, IM Silverman, SS Tummala, ... Acta neuropathologica 136, 779-792, 2018 | 81 | 2018 |
Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic EA Williams, S Santagata, H Wakimoto, GM Shankar, FG Barker, R Sharaf, ... Acta neuropathologica communications 8, 1-10, 2020 | 79 | 2020 |
Absence of Alzheimer disease neuropathologic changes in eyes of subjects with Alzheimer disease EA Williams, D McGuone, MP Frosch, BT Hyman, N Laver, ... Journal of Neuropatholgy & Experimental Neurology 76 (5), 376-383, 2017 | 63 | 2017 |
Srcasm inhibits Fyn-induced cutaneous carcinogenesis with modulation of Notch1 and p53 L Zhao, W Li, C Marshall, T Griffin, M Hanson, R Hick, T Dentchev, ... Cancer research 69 (24), 9439-9447, 2009 | 59 | 2009 |
Genotype-targeted local therapy of glioma GM Shankar, AR Kirtane, JJ Miller, H Mazdiyasni, J Rogner, T Tai, ... Proceedings of the National Academy of Sciences 115 (36), E8388-E8394, 2018 | 52 | 2018 |
Accelerated progression of IDH mutant glioma after first recurrence JJ Miller, F Loebel, TA Juratli, SS Tummala, EA Williams, TT Batchelor, ... Neuro-oncology 21 (5), 669-677, 2019 | 49 | 2019 |
PI3K/AKT/mTOR pathway alterations promote malignant progression and xenograft formation in oligodendroglial tumors K Tateishi, T Nakamura, TA Juratli, EA Williams, Y Matsushita, S Miyake, ... Clinical Cancer Research 25 (14), 4375-4387, 2019 | 44 | 2019 |
Histone H3K27 dimethyl loss is highly specific for malignant peripheral nerve sheath tumor and distinguishes true PRC2 loss from isolated H3K27 trimethyl loss DM Marchione, A Lisby, AN Viaene, M Santi, ML Nasrallah, LP Wang, ... Modern Pathology 32 (10), 1434-1446, 2019 | 43 | 2019 |
JAK2 rearrangements are a recurrent alteration in CD30+ systemic T-cell lymphomas with anaplastic morphology MJ Fitzpatrick, LR Massoth, C Marcus, JA Vergilio, E Severson, D Duncan, ... The American Journal of Surgical Pathology 45 (7), 895-904, 2021 | 37 | 2021 |
Frequent inactivating mutations of the PBAF complex gene PBRM1 in meningioma with papillary features EA Williams, H Wakimoto, GM Shankar, FG Barker, PK Brastianos, ... Acta neuropathologica 140, 89-93, 2020 | 37 | 2020 |
Histiocytic and dendritic cell sarcomas of hematopoietic origin share targetable genomic alterations distinct from follicular dendritic cell sarcoma LR Massoth, YP Hung, JA Ferry, RP Hasserjian, V Nardi, GP Nielsen, ... The Oncologist 26 (7), e1263-e1272, 2021 | 34 | 2021 |
Pan-Cancer Landscape Analysis Reveals Recurrent KMT2A-MAML2 Gene Fusion in Aggressive Histologic Subtypes of Thymoma LR Massoth, YP Hung, D Dias-Santagata, M Onozato, N Shah, ... JCO precision oncology 4, 109-115, 2020 | 33 | 2020 |
Melanomas with activating RAF1 fusions: clinical, histopathologic, and molecular profiles EA Williams, N Shah, M Montesion, R Sharaf, DC Pavlick, ES Sokol, ... Modern Pathology 33 (8), 1466-1474, 2020 | 32 | 2020 |
Vulvar squamous cell carcinoma: comprehensive genomic profiling of HPV+ versus HPV–forms reveals distinct sets of potentially actionable molecular targets EA Williams, AJ Werth, R Sharaf, M Montesion, ES Sokol, DC Pavlick, ... JCO Precision Oncology 4, 647-661, 2020 | 32 | 2020 |
Melanoma with in-frame deletion of MAP2K1: A distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations EA Williams, M Montesion, N Shah, R Sharaf, DC Pavlick, ES Sokol, ... Modern pathology 33 (12), 2397-2406, 2020 | 27 | 2020 |
Pan-sarcoma genomic analysis of KMT2A rearrangements reveals distinct subtypes defined by YAP1–KMT2A–YAP1 and VIM–KMT2A fusions LR Massoth, YP Hung, V Nardi, GP Nielsen, RP Hasserjian, ... Modern Pathology 33 (11), 2307-2317, 2020 | 26 | 2020 |